Keywords: GlaxoSmithKline, Theravance, Relovair, COPD, Asthma, Regulatory filing, Research results

GSK and Theravance to file COPD/asthma drug

Article | 10 January 2012

Print This

UK pharma giant GlaxoSmithKline (LSE: GSK) and partner USA-based Theravance (Nasdaq: THRX), in which GSK has acquired a 19% equity stake ( ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in